ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...

Clinical Solutions appoints three C-suite executives to lead product, finance, and talent functions amid strong first-half ...

WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...

A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape ...

MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a ...

Arcus Biosciences has $694M in cash to advance its pipeline through pivotal trials, including the Phase 3 PRISM-1 study of ...

Novartis's pelacarsen hit its Lp(a) target in 8,323 patients but missed the cardiovascular endpoint entirely, exposing a $6B ...

FDA AI Guidance requires clinical trial sponsors to validate algorithms before submission, shifting documentation and testing ...

YPrime names Greg Wellbrock Chief Data and AI Officer to lead unified data and AI strategy across its clinical trial ...

Fifth Circuit vacates class certification in Filana Therapeutics securities case, removing litigation overhang as company ...

FDA clears Fresenius multiFiltratePRO for regional citrate anticoagulation in acute kidney injury, with integrated pumps and ...

Hengrui Pharma presents Phase 3 ruzaltatug data at ESMO 2026, showing progression-free survival endpoint met in EGFR-mutated ...